scholarly journals Role of Chest CT in COVID-19

2021 ◽  
Vol 11 ◽  
pp. 30
Author(s):  
Nagina Malguria ◽  
Li-Hsiang Yen ◽  
Tony Lin ◽  
Amira Hussein ◽  
Elliot K. Fishman
Keyword(s):  
Early Stage ◽  
High Sensitivity ◽  
Connective Tissue Disorders ◽  
Reticular Pattern ◽  
Ct Findings ◽  
High Incidence ◽  
Reversed Halo Sign ◽  
Traction Bronchiectasis ◽  
Progressive Stage

In December 2019, a disease attributed to a new severe acute respiratory syndrome coronavirus 2, and named coronavirus disease 2019 (COVID-19), broke out in Wuhan, China and has spread rapidly throughout the world. CT has been advocated in selected indications as a tool toward rapid and early diagnosis. The CT patterns of COVID-19 include ground glass opacities GGO, consolidation, and crazy paving. Additional signs include a “rounded morphology” of lesions, vascular enlargement sign, nodules, and fibrous stripe. Signs of healing and organization include subpleural bands, a reticular pattern, reversed halo sign and traction bronchiectasis. Cavitation and tree in bud signs are absent and pleural effusions are rare. There is a high incidence of pulmonary embolism associated with COVID-19. CT findings in COVID-19 appear to follow a predictable timeline with maximal involvement approximately 6–11 days after symptom onset. The stages of evolution include early stage (days 0–4) with GGO being the predominant abnormality, progressive stage (days 5–8) with increasing crazy paving; and peak stage (days 9–13) with predominance of consolidation and absorption phase (after day 14) with gradual absorption of consolidation with residual GGO and subpleural bands. CT findings in COVID-19 have a high sensitivity and low specificity, determined to be 98% and 25% in a retrospective study of 1014 patients. The low specificity of CT for the diagnosis of COVID-19 pneumonia is due to the overlap of CT findings with other viral pneumonias and other infections, lung involvement in connective tissue disorders, drug reaction, pulmonary edema, and hemorrhage.

Markers of the early stage of rheumatoid arthritis

2016 ◽  
Vol 51 (4) ◽  
pp. 305-314
Author(s):  
Beata Polińska ◽  
Joanna Matowicka-Karna ◽  
Halina Kemona
Keyword(s):  
Rheumatoid Arthritis ◽  
Human Population ◽  
Early Stage ◽  
Clinical Signs ◽  
High Sensitivity ◽  
Unknown Etiology ◽  
Serological Tests ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Rheumatoid arthritis (RA) is a chronic, autoimmune connective tissue disease of unknown etiology. RA affects about 1% of the human population, women suffer three times more often than men, with the peak incidence between the age of 40 to 50. The up-to-date criteria from 2010 for the diagnosis of RA include: occurrence and duration of clinical signs, indicators of inflammation and serological tests. Neopterin, a protein released by macrophages, is a sensitive indicator of inflammation and the severity of RA. Regarding the serological tests, anti-cyclic citrullinated peptide antibodies represent a well-known marker with the specificity for RA of about 98%. The antibodies may be present in the serum of patients even a few years before the first clinical signs of the disease, heralding erosive changes in the joints and more severe course of RA. The literature also contains reports about autoantibodies anti-CarP and anti-Sa/ anti-MCV, which may occur in people with pain and swelling of joints and precede full-blown development of RA as well as reflect disease activity. Serological diagnosis of RA may be supported by some genetic tests based on PCR for detecting mutations e.g. C1858T in the PNPN22 gene. In turn, the quantitative analysis of different classes of miRNAs seems justified in order to better classify patients showing symptoms of RA. Further studies are needed that take into account the role of different markers in the development of RA, and confirm the high sensitivity and specificity of these markers in the diagnosis of the disease.

scholarly journals The Role of Chest High Resolution CT and Rt-Pcr in Diagnosis of Different Stages of Coronavirus (Covid-19) Pneumonia

2021 ◽  
Vol 02 ◽  
Author(s):  
Mohamed N.E. Kassem ◽  
Doaa T. Masallat
Keyword(s):  
High Resolution ◽  
Early Stage ◽  
Rt Pcr ◽  
High Resolution Computed Tomography ◽  
Severe Stage ◽  
Normal Chest ◽  
Patient’S Outcome ◽  
A Prospective Study ◽  
Progressive Stage

Purpose: To investigate how RT-PCR (real time–polymerase-chain-reaction) and chest High Resolution Computed Tomography (HRCT) can detect COVID-19 (Coronavirus Disease 19) disease in the early, progressive and severe stages, as well as patient’s outcome. Method: We perform a prospective study with chest HRCT on 206 patients with positive RT-PCR test. The patients were divided into three groups; early stage (100 patients), progressive stage (70 patients) and severe stage (36 patients). Results: The early stage involved typical category (COVID-19 Reporting and Data System, CO-RADS 5, 34 cases - 34%), indeterminate category (CO-RADS 3, six cases - 6%), atypical category (CO-RADS 4, ten cases - 10%) and normal chest HRCT imaging (CO-RADS 1, 50 cases - 50%). The progressive stage involved typical category (CO-RADS 5, 70 cases, 100%), The severe stage involved typical category (CO-RADS 5, 36 cases, 100 %). Conclusion: RT-PCR is the gold standard and specific tool for confirming COVID-19 infection. Combination of RT-PCR and chest HRCT is used for early diagnosis of COVID-19 pneumonia. Chest HRCT is positive in 50% of patients in the early stage of COVID-19. Chest HRCT is not only detecting pulmonary parenchymal changes but also determining patient’s outcome in the progressive and severe stages of COVID-19 (CO-RADS 5). Patients with progressive stage will not need ventilator and patients with severe stage should receive ventilator.

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

2012 ◽  
Vol 30 (15) ◽  
pp. 1879-1887 ◽  
Author(s):  
Otto Metzger-Filho ◽  
Andrew Tutt ◽  
Evandro de Azambuja ◽  
Kamal S. Saini ◽  
Giuseppe Viale ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Parp Inhibitor ◽  
High Sensitivity ◽  
Phase Iii ◽  
Breast Cancers ◽  
Cancer Subtypes

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes. This is observed despite its usual high sensitivity to chemotherapy. In the advanced setting, responses observed with chemotherapy lack durability. Early-stage clinical studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction. The molecular complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies. In this review, we discuss the biology of TNBC at the pathologic and the molecular levels. We also elaborate on the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC.

Role of high sensitivity C - Reactive protein and some of heavy metals in patients with rheumatoid arthritis

2020 ◽  
Vol 23 (16) ◽  
Author(s):  
Nashwan S. Albabawaty ◽  
Ali Y. Majid ◽  
Mohammed H. Alosami ◽  
Halla G. Mahmood
Keyword(s):  
Rheumatoid Arthritis ◽  
Heavy Metals ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein

Recent Progress in the Analysis of Captopril Using Electrochemical Methods: A Review

2019 ◽  
Vol 15 (3) ◽  
pp. 198-206 ◽  
Author(s):  
Sarfaraz Ahmed Mahesar ◽  
Saeed Ahmed Lakho ◽  
Syed Tufail Hussain Sherazi ◽  
Hamid Ali Kazi ◽  
Kamran Ahmed Abro ◽  
...  
Keyword(s):  
Enzyme Inhibitor ◽  
Modified Electrodes ◽  
High Sensitivity ◽  
Pharmaceutical Formulations ◽  
Inorganic Materials ◽  
Electrochemical Methods ◽  
Nano Particles ◽  
Moderate Heart Failure ◽  
Analytical Instrumentation

Background: Captopril is the synthetic dipeptide used as an angiotensin converting enzyme inhibitor. Captopril is used to treat hypertension as well as for the treatment of moderate heart failure. Analytical instrumentation and methodology plays an important role in pharmaceutical analysis. Methods: This review presents some important applications of electrochemical modes used for the analysis of captopril. So far captopril has been analyzed by using different bare and modified working electrodes with a variety of modifiers from organic and inorganic materials to various types of nano particles/materials. Results: This paper presents some of the methods which have been published in the last few years i.e. from 2003 to 2016. This review highlights the role of the analytical instrumentation, particularly electrochemical methods in assessing captopril using various working electrodes. Conclusion: A large number of studies on voltammetry noted by means of various bare and modified electrodes. Among all of the published voltammetric methods, DPV, SWV, CV and miscellaneous modes were trendy techniques used to analyze captopril in pharmaceutical formulations as well as biological samples. Electrodes modified with nanomaterials are promising sensing tools as this showed high sensitivity, good accuracy with precision as well as selectivity. In comparison to chromatographic methods, the main advantages of electrochemical methods are its cheaper instrumentation, lower detection limit and minimal or no sample preparation.

Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer

2015 ◽  
Vol 10 (2) ◽  
pp. 101-110 ◽  
Author(s):  
Matias E. Valsecchi ◽  
Gerrit Kimmey ◽  
Arvinder Bir ◽  
Damian Silbermins
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Early Stage Breast Cancer

Board of Director Characteristics, Institutional Ownership, and Fraud: Evidence from Australia

2004 ◽  
Vol 23 (2) ◽  
pp. 105-117 ◽  
Author(s):  
Vineeta D. Sharma
Keyword(s):  
Research Evidence ◽  
Institutional Ownership ◽  
Board Of Director ◽  
Composition And Structure ◽  
High Incidence ◽  
The Board Of Directors ◽  
Director Characteristics ◽  
The Relationship ◽  
The U.S

Due to the high incidence of fraud in Australia, regulatory reports suggest strengthening the monitoring role of the board of directors (BOD). These reports recommend greater independence and no duality (chairperson of the BOD should not be the CEO) on the BOD. While there is no Australian evidence, research evidence in the U.S. supports these suggested reforms. It is not clear whether the research evidence observed in the U.S. will generalize to the Australian setting because of contextual differences. This study extends the U.S. findings to the Australian context and investigates the relationship between two attributes of the BOD, independence and duality, and fraud. In addition, I examine whether institutional ownership plays a role in the context of fraud. The more highly concentrated institutional ownership in Australia suggests the presence of some relationship. Using a matched sample of fraud and no-fraud firms from 1988–2000, I find that as the percentage of independent directors and the percentage of independent institutional ownership increases, the likelihood of fraud decreases. As expected, the results show a positive relationship between duality and the likelihood of fraud. These results support the call for strengthening the composition and structure of the BOD in Australia.

Sign in / Sign up

Export Citation Format

Share Document